ADMA Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Revenue	258.22	154.08	80.94	42.22	29.35	Upgrade
Revenue Growth (YoY)	67.59%	90.36%	91.72%	43.85%	72.79%	Upgrade
Cost of Revenue	169.27	118.82	79.77	61.29	39.5	Upgrade
Gross Profit	88.94	35.27	1.17	-19.07	-10.16	Upgrade
Selling, General & Admin	59.02	52.46	42.9	35.05	25.91	Upgrade
Research & Development	3.3	3.61	3.65	5.91	2.34	Upgrade
Other Operating Expenses	4.99	18.56	13	4.89	3.01	Upgrade
Operating Expenses	67.31	74.63	59.55	45.84	31.27	Upgrade
Operating Income	21.63	-39.37	-58.37	-64.91	-41.42	Upgrade
Interest Expense / Income	25.03	19.28	13.06	11.99	8.99	Upgrade
Other Expense / Income	24.84	7.26	0.22	-1.15	-2.14	Upgrade
Pretax Income	-28.24	-65.9	-71.65	-75.75	-48.28	Upgrade
Net Income	-28.24	-65.9	-71.65	-75.75	-48.28	Upgrade
Shares Outstanding (Basic)	224	198	140	86	54	Upgrade
Shares Outstanding (Diluted)	224	198	140	86	54	Upgrade
Shares Change	13.19%	41.77%	62.03%	58.51%	20.27%	Upgrade
EPS (Basic)	-0.13	-0.33	-0.51	-0.88	-0.89	Upgrade
EPS (Diluted)	-0.13	-0.33	-0.51	-0.88	-0.89	Upgrade
Free Cash Flow	4.03	-73.42	-125.88	-114.73	-80.01	Upgrade
Free Cash Flow Per Share	0.02	-0.37	-0.90	-1.33	-1.47	Upgrade
Gross Margin	34.44%	22.89%	1.45%	-45.17%	-34.60%	Upgrade
Operating Margin	8.38%	-25.55%	-72.12%	-153.75%	-141.14%	Upgrade
Profit Margin	-10.94%	-42.77%	-88.52%	-179.41%	-164.50%	Upgrade
Free Cash Flow Margin	1.56%	-47.65%	-155.52%	-271.74%	-272.60%	Upgrade
EBITDA	5.12	-39.51	-53.1	-59.82	-36.03	Upgrade
EBITDA Margin	1.98%	-25.64%	-65.60%	-141.69%	-122.76%	Upgrade
Depreciation & Amortization	8.33	7.11	5.5	3.94	3.26	Upgrade
EBIT	-3.21	-46.63	-58.59	-63.76	-39.29	Upgrade
EBIT Margin	-1.24%	-30.26%	-72.39%	-151.03%	-133.86%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).